ProCE Banner Activity

INTEGRATE: Regorafenib Prolonged PFS in Previously Treated GE Cancer

Slideset Download
Conference Coverage
This slideset covers the final and subgroup results of the INTEGRATE phase II trial of regorafenib in refractory advanced gastroesophageal cancer as presented at the 2015 ASCO meeting.

Released: June 01, 2015

Expiration: May 30, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation